Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Analysis of Cancer Genomic Amplifications Identifies Druggable Collateral Dependencies within the Amplicon

  • Pons Barcons, Guillem
  • Gallo, Gabriel Osvaldo
  • Zarzosa Martinez, Patricia
  • Magdaleno Cazon, Ainara
  • Segura Ginard, Miguel
  • Sánchez de Toledo Codina, Josep
  • Gallego Melcón, Soledad
  • Moreno Martín-Retortillo, Lucas
  • Roma Castanyer, Josep
  • Navarro Barea, Natalia
  • Sansa Girona, Júlia
  • Garcia Gilabert, Lia
Cancer; Drug development; Gene amplifications, Cáncer; Desarrollo de fármacos; Amplificaciones de genes, Càncer; Desenvolupament de medicaments; Amplificacions de gens, The identification of novel therapeutic targets for specific cancer molecular subtypes is crucial for the development of precision oncology. In the last few years, CRISPR/Cas9 screens have accelerated the discovery and validation of new targets associated with different tumor types, mutations, and fusions. However, there are still many cancer vulnerabilities associated with specific molecular features that remain to be explored. Here, we used data from CRISPR/Cas9 screens in 954 cancer cell lines to identify gene dependencies associated with 16 common cancer genomic amplifications. We found that high-copy-number genomic amplifications generate multiple collateral dependencies within the amplified region in most cases. Further, to prioritize candidate targets for each chromosomal region amplified, we integrated gene dependency parameters with both druggability data and subcellular location. Finally, analysis of the relationship between gene expression and gene dependency led to the identification of genes, the expression of which may constitute predictive biomarkers of dependency. In conclusion, our study provides a set of druggable targets specific for each amplification, opening the possibility to specifically target amplified tumors on this basis., This research was funded by grants from Institut Català d’Oncologia (ICO), Instituto de Salud Carlos III (PI21/00640), AGAUR (2021 FI_B 00088), Fundació BOSCH, Iniciativa Tot per tu, Fundació Amics Joan Petit, and Mi compañero de viaje.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma

  • Gallo-Oller, Gabriel
  • Pons , Guillem
  • Sansa Girona, Júlia
  • Navarro Barea, Natalia
  • Zarzosa, Patricia
  • Garcia Gilabert, Lia
  • Cabré-Fernandez, Paula
  • Valero-Arrese, Lorena
  • Lizcano De Vega, Jose Miguel
  • Sánchez de Toledo Codin, Josep
  • Roma, Josep
  • Segura, Miguel F.
  • Gallego, Soledad
  • Moreno, Lucas
  • Guillén Burrieza, Gabriela
Fusion protein; Rhabdomyosarcoma, Proteïna de fusió; Rabdomiosarcoma, Proteína de fusión; Rabdomiosarcoma, Rhabdomyosarcoma (RMS), such as other childhood tumors, has witnessed treatment advancements in recent years. However, high-risk patients continue to face poor survival rates, often attributed to the presence of the PAX3/7-FOXO1 fusion proteins, which has been associated with metastasis and treatment resistance. Despite efforts to directly target these chimeric proteins, clinical success remains elusive. In this study, the main aim was to address this challenge by investigating regulators of FOXO1. Specifically, we focused on TRIB3, a potential regulator of the fusion protein in RMS. Our findings revealed a prominent TRIB3 expression in RMS tumors, highlighting its correlation with the presence of fusion protein. By conducting TRIB3 genetic inhibition experiments, we observed an impairment on cell proliferation. Notably, the knockdown of TRIB3 led to a decrease in PAX3-FOXO1 and its target genes at protein level, accompanied by a reduction in the activity of the Akt signaling pathway. Additionally, inducible silencing of TRIB3 significantly delayed tumor growth and improved overall survival in vivo. Based on our analysis, we propose that TRIB3 holds therapeutic potential for treating the most aggressive subtype of RMS. The findings herein reported contribute to our understanding of the underlying molecular mechanisms driving RMS progression and provide novel insights into the potential use of TRIB3 as a therapeutic intervention for high-risk RMS patients., This research was funded by grants from Institut Català d’Oncologia (ICO), Instituto de Salud Carlos III (PI21/00640), Fundació la Marató de TV3, Fundació BOSCH, Iniciativa Tot per tu, Fundació Amics Joan Petit, Fundación Inocente, and Mi compañero de viaje.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Dickkopf Proteins and Their Role in Cancer: A Family of Wnt Antagonists with a Dual Role

  • Giralt Buch, Irina
  • Gallo, Gabriel Osvaldo
  • Zarzosa Martinez, Patricia
  • Pons Barcons, Guillem
  • Magdaleno Cazon, Ainara
  • Segura Ginard, Miguel
  • Sánchez de Toledo Codina, Josep
  • Moreno Martín-Retortillo, Lucas
  • Gallego Melcón, Soledad
  • Roma Castanyer, Josep
  • Navarro Barea, Natalia
Dickkopf; Wnt antagonists; Wnt signaling, Dickkopf; Antagonistes Wnt; Senyalització Wnt, Dickkopf; Antagonistas Wnt; Señalización Wnt, The Wnt signaling pathway regulates crucial aspects such as cell fate determination, cell polarity and organogenesis during embryonic development. Wnt pathway deregulation is a hallmark of several cancers such as lung, gastric and liver cancer, and has been reported to be altered in others. Despite the general agreement reached by the scientific community on the oncogenic potential of the central components of the pathway, the role of the antagonist proteins remains less clear. Deregulation of the pathway may be caused by overexpression or downregulation of a wide range of antagonist proteins. Although there is growing information related to function and regulation of Dickkopf (DKK) proteins, their pharmacological potential as cancer therapeutics still has not been fully developed. This review provides an update on the role of DKK proteins in cancer and possible potential as therapeutic targets for the treatment of cancer; available compounds in pre-clinical or clinical trials are also reviewed., This work was supported by grants from Institut Català d’Oncologia (ICO); Instituto de Salud Carlos III (PI18/00398 and PI21/00640); La Marató de TV3 (201937); Fundació A.BOSCH; Rotary Clubs Barcelona Eixample, Barcelona Diagonal, Santa Coloma de Gramanet, München-Blutenburg, Deutschland Gemeindienst e.V. and others from Barcelona and province; Eric Abidal Foundation and Mi compañero de viaje.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Analysis of Cancer Genomic Amplifications Identifies Druggable Collateral Dependencies within the Amplicon

  • Pons, Guillem|||0000-0001-8128-740X
  • Gallo Oller, Gabriel|||0000-0002-3864-1941
  • Navarro Barea, Natalia|||0000-0002-2160-6656
  • Zarzosa, Patricia|||0000-0002-9711-8384
  • Sansa-Girona, Júlia|||0000-0003-3285-7845
  • García-Gilabert, Lia|||0000-0003-2079-7232
  • Magdaleno, Ainara|||0000-0002-2718-3244
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Gallego, Soledad|||0000-0002-4712-9624
  • Moreno Martin Retortillo, Lucas|||0000-0002-0708-1670
  • Roma, Josep|||0000-0001-7692-6123
The identification of novel therapeutic targets for specific cancer molecular subtypes is crucial for the development of precision oncology. In the last few years, CRISPR/Cas9 screens have accelerated the discovery and validation of new targets associated with different tumor types, mutations, and fusions. However, there are still many cancer vulnerabilities associated with specific molecular features that remain to be explored. Here, we used data from CRISPR/Cas9 screens in 954 cancer cell lines to identify gene dependencies associated with 16 common cancer genomic amplifications. We found that high-copy-number genomic amplifications generate multiple collateral dependencies within the amplified region in most cases. Further, to prioritize candidate targets for each chromosomal region amplified, we integrated gene dependency parameters with both druggability data and subcellular location. Finally, analysis of the relationship between gene expression and gene dependency led to the identification of genes, the expression of which may constitute predictive biomarkers of dependency. In conclusion, our study provides a set of druggable targets specific for each amplification, opening the possibility to specifically target amplified tumors on this basis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dickkopf Proteins and Their Role in Cancer, A Family of Wnt Antagonists with a Dual Role

  • Giralt, Irina|||0000-0002-9094-4325
  • Gallo Oller, Gabriel|||0000-0002-3864-1941
  • Navarro Barea, Natalia|||0000-0002-2160-6656
  • Zarzosa, Patricia|||0000-0002-9711-8384
  • Pons, Guillem|||0000-0001-8128-740X
  • Magdaleno, Ainara|||0000-0002-2718-3244
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Sánchez de Toledo, Joan|||0000-0002-9108-4750
  • Moreno Martin Retortillo, Lucas|||0000-0002-0708-1670
  • Gallego, Soledad|||0000-0002-4712-9624
  • Roma, Josep|||0000-0001-7692-6123
The Wnt signaling pathway regulates crucial aspects such as cell fate determination, cell polarity and organogenesis during embryonic development. Wnt pathway deregulation is a hallmark of several cancers such as lung, gastric and liver cancer, and has been reported to be altered in others. Despite the general agreement reached by the scientific community on the oncogenic potential of the central components of the pathway, the role of the antagonist proteins remains less clear. Deregulation of the pathway may be caused by overexpression or downregulation of a wide range of antagonist proteins. Although there is growing information related to function and regulation of Dickkopf (DKK) proteins, their pharmacological potential as cancer therapeutics still has not been fully developed. This review provides an update on the role of DKK proteins in cancer and possible potential as therapeutic targets for the treatment of cancer; available compounds in pre-clinical or clinical trials are also reviewed.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Analysis of Cancer Genomic Amplifications Identifies Druggable Collateral Dependencies within the Amplicon

  • Pons Barcons, Guillem
  • Gallo, Gabriel Osvaldo
  • Zarzosa Martinez, Patricia
  • Magdaleno Cazon, Ainara
  • Segura Ginard, Miguel
  • Sánchez de Toledo Codina, Josep
  • Gallego Melcón, Soledad
  • Moreno Martín-Retortillo, Lucas
  • Roma Castanyer, Josep
  • Navarro Barea, Natalia
  • Sansa Girona, Júlia
  • Garcia Gilabert, Lia
Cancer; Drug development; Gene amplifications, Cáncer; Desarrollo de fármacos; Amplificaciones de genes, Càncer; Desenvolupament de medicaments; Amplificacions de gens, The identification of novel therapeutic targets for specific cancer molecular subtypes is crucial for the development of precision oncology. In the last few years, CRISPR/Cas9 screens have accelerated the discovery and validation of new targets associated with different tumor types, mutations, and fusions. However, there are still many cancer vulnerabilities associated with specific molecular features that remain to be explored. Here, we used data from CRISPR/Cas9 screens in 954 cancer cell lines to identify gene dependencies associated with 16 common cancer genomic amplifications. We found that high-copy-number genomic amplifications generate multiple collateral dependencies within the amplified region in most cases. Further, to prioritize candidate targets for each chromosomal region amplified, we integrated gene dependency parameters with both druggability data and subcellular location. Finally, analysis of the relationship between gene expression and gene dependency led to the identification of genes, the expression of which may constitute predictive biomarkers of dependency. In conclusion, our study provides a set of druggable targets specific for each amplification, opening the possibility to specifically target amplified tumors on this basis., This research was funded by grants from Institut Català d’Oncologia (ICO), Instituto de Salud Carlos III (PI21/00640), AGAUR (2021 FI_B 00088), Fundació BOSCH, Iniciativa Tot per tu, Fundació Amics Joan Petit, and Mi compañero de viaje.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma

  • Gallo-Oller, Gabriel
  • Pons , Guillem
  • Sansa Girona, Júlia
  • Navarro Barea, Natalia
  • Zarzosa, Patricia
  • Garcia Gilabert, Lia
  • Cabré-Fernandez, Paula
  • Valero-Arrese, Lorena
  • Lizcano De Vega, Jose Miguel
  • Sánchez de Toledo Codin, Josep
  • Roma, Josep
  • Segura, Miguel F.
  • Gallego, Soledad
  • Moreno, Lucas
  • Guillén Burrieza, Gabriela
Fusion protein; Rhabdomyosarcoma, Proteïna de fusió; Rabdomiosarcoma, Proteína de fusión; Rabdomiosarcoma, Rhabdomyosarcoma (RMS), such as other childhood tumors, has witnessed treatment advancements in recent years. However, high-risk patients continue to face poor survival rates, often attributed to the presence of the PAX3/7-FOXO1 fusion proteins, which has been associated with metastasis and treatment resistance. Despite efforts to directly target these chimeric proteins, clinical success remains elusive. In this study, the main aim was to address this challenge by investigating regulators of FOXO1. Specifically, we focused on TRIB3, a potential regulator of the fusion protein in RMS. Our findings revealed a prominent TRIB3 expression in RMS tumors, highlighting its correlation with the presence of fusion protein. By conducting TRIB3 genetic inhibition experiments, we observed an impairment on cell proliferation. Notably, the knockdown of TRIB3 led to a decrease in PAX3-FOXO1 and its target genes at protein level, accompanied by a reduction in the activity of the Akt signaling pathway. Additionally, inducible silencing of TRIB3 significantly delayed tumor growth and improved overall survival in vivo. Based on our analysis, we propose that TRIB3 holds therapeutic potential for treating the most aggressive subtype of RMS. The findings herein reported contribute to our understanding of the underlying molecular mechanisms driving RMS progression and provide novel insights into the potential use of TRIB3 as a therapeutic intervention for high-risk RMS patients., This research was funded by grants from Institut Català d’Oncologia (ICO), Instituto de Salud Carlos III (PI21/00640), Fundació la Marató de TV3, Fundació BOSCH, Iniciativa Tot per tu, Fundació Amics Joan Petit, Fundación Inocente, and Mi compañero de viaje.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Dickkopf Proteins and Their Role in Cancer: A Family of Wnt Antagonists with a Dual Role

  • Giralt Buch, Irina
  • Gallo, Gabriel Osvaldo
  • Zarzosa Martinez, Patricia
  • Pons Barcons, Guillem
  • Magdaleno Cazon, Ainara
  • Segura Ginard, Miguel
  • Sánchez de Toledo Codina, Josep
  • Moreno Martín-Retortillo, Lucas
  • Gallego Melcón, Soledad
  • Roma Castanyer, Josep
  • Navarro Barea, Natalia
Dickkopf; Wnt antagonists; Wnt signaling, Dickkopf; Antagonistes Wnt; Senyalització Wnt, Dickkopf; Antagonistas Wnt; Señalización Wnt, The Wnt signaling pathway regulates crucial aspects such as cell fate determination, cell polarity and organogenesis during embryonic development. Wnt pathway deregulation is a hallmark of several cancers such as lung, gastric and liver cancer, and has been reported to be altered in others. Despite the general agreement reached by the scientific community on the oncogenic potential of the central components of the pathway, the role of the antagonist proteins remains less clear. Deregulation of the pathway may be caused by overexpression or downregulation of a wide range of antagonist proteins. Although there is growing information related to function and regulation of Dickkopf (DKK) proteins, their pharmacological potential as cancer therapeutics still has not been fully developed. This review provides an update on the role of DKK proteins in cancer and possible potential as therapeutic targets for the treatment of cancer; available compounds in pre-clinical or clinical trials are also reviewed., This work was supported by grants from Institut Català d’Oncologia (ICO); Instituto de Salud Carlos III (PI18/00398 and PI21/00640); La Marató de TV3 (201937); Fundació A.BOSCH; Rotary Clubs Barcelona Eixample, Barcelona Diagonal, Santa Coloma de Gramanet, München-Blutenburg, Deutschland Gemeindienst e.V. and others from Barcelona and province; Eric Abidal Foundation and Mi compañero de viaje.